[{"address1": "4300 El Camino Real", "address2": "Suite 210", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 351 4495", "website": "https://unicycive.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.", "fullTimeEmployees": 14, "maxAge": 86400, "priceHint": 4, "previousClose": 0.63, "open": 0.6367, "dayLow": 0.62, "dayHigh": 0.65, "regularMarketPreviousClose": 0.63, "regularMarketOpen": 0.6367, "regularMarketDayLow": 0.62, "regularMarketDayHigh": 0.65, "beta": 2.539, "forwardPE": -2.6475, "volume": 285560, "regularMarketVolume": 285560, "averageVolume": 392691, "averageVolume10days": 347870, "averageDailyVolume10Day": 347870, "bid": 0.6136, "ask": 0.6794, "bidSize": 100, "askSize": 100, "marketCap": 23895234, "fiftyTwoWeekLow": 0.47, "fiftyTwoWeekHigh": 1.818, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 0.966, "twoHundredDayAverage": 0.93736, "currency": "USD", "enterpriseValue": 21867252, "floatShares": 14777525, "sharesOutstanding": 37606600, "sharesShort": 859772, "sharesShortPriorMonth": 382933, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0229, "heldPercentInsiders": 0.16896999, "heldPercentInstitutions": 0.60543, "shortRatio": 2.14, "shortPercentOfFloat": 0.027999999, "impliedSharesOutstanding": 37606600, "bookValue": -0.65, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -37815000, "trailingEps": -0.92, "forwardEps": -0.24, "enterpriseToEbitda": -0.849, "52WeekChange": -0.62426037, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "UNCY", "underlyingSymbol": "UNCY", "shortName": "Unicycive Therapeutics, Inc.", "longName": "Unicycive Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626096600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8b289956-33cd-3aa2-beed-9487631afaeb", "messageBoardId": "finmb_605176729", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6354, "targetHighPrice": 9.0, "targetLowPrice": 3.0, "targetMeanPrice": 5.3, "targetMedianPrice": 4.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 48930000, "totalCashPerShare": 1.301, "ebitda": -25760000, "totalDebt": 715000, "quickRatio": 1.616, "currentRatio": 1.706, "debtToEquity": 3.29, "returnOnAssets": -0.40484002, "returnOnEquity": -2.2905, "freeCashflow": -165250, "operatingCashflow": -20819000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]